Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone

Journal of Human Hypertension volume 15, pages 495–498 (2001)Cite this article

Abstract

Objective: To compare the efficacy, tolerability, and safety of once-daily therapy with amlodipine 5 mg/benazepril 10 mg vs amlodipine 5 mg, benazepril 10 mg, and placebo.

Design: Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial.

Setting: Twenty-two clinical centres, including private practice groups and academic research clinics.

Patients: A total of 530 patients between 21 and 80 years of age with essential hypertension were screened for the study, and 454 were randomised to treatment with amlodipine 5 mg/benazepril 10 mg, amlodipine 5 mg, benazepril 10 mg, or placebo for 8 weeks.

Results: Amlodipine 5 mg/benazepril 10 mg produced greater reductions from baseline in sitting diastolic blood pressure than amlodipine 5 mg (P < 0.03), benazepril 10 mg (P < 0.001), and placebo (P < 0.001). The response rate in the amlodipine 5-mg/benazepril 10-mg treatment group (66.4%) was better than that observed in the amlodipine 5-mg (50.0% P < 0.02), benazepril 10-mg (38.3% P < 0.001), and placebo (24.4% P < 0.001) groups. There was no significant difference in heart rate among the four groups. The incidence of oedema in the amlodipine 5-mg/benazepril 10-mg (1.7%) group was somewhat less than that in the amlodipine 5-mg (4.5%) group.

Conclusions: Therapy with amlodipine 5 mg/benazepril 10 mg was well tolerated and was superior to amlodipine 5 mg, benazepril 10 mg, and placebo in reducing sitting diastolic blood pressure in patients with essential hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Frishman WH et alComparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril inpatients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group J Clin Pharmacol 1995 35 1060–1066

    Article  CAS  Google Scholar 

  2. Frishman WH, Landau A, Cretkovic A Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension J Clin Pharmacol 1993 33 752–755

    Article  CAS  Google Scholar 

  3. White WB, Viadero JJ, Lane TJ, Podesla S Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension Clin Pharmacol Ther 1986 39 43–48

    Article  CAS  Google Scholar 

  4. Guazzi MD et alCalcium-channel blockade with nifedipine and angiotensin coverting-enzyme inhibition with captopril in the therapy ofpatients with severe primary hypertension Circulation 1984 70 279–284

    Article  CAS  Google Scholar 

  5. 1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting J Hypertens 1989 7 689–693

Download references

Acknowledgements

This study was supported by a research grant from Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

Author information

Authors and Affiliations

  1. The Methodist Hospital, Houston, TX, USA

    J Pool

  2. Humana Hospital, San Antonio, TX, USA

    P Kaihlanen

  3. Clinical Pharmacology Center, New Bedford, MA, USA

    G Lewis

  4. Harleysville Medical Association, Harleysville, PA, USA

    D Ginsberg

  5. University of Alabama Medical Center, Birmingham, AL, USA

    S Oparil

  6. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

    R Glazer

  7. Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA, USA

    FH Messerli

Authors
  1. J Pool
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Kaihlanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Oparil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Glazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. FH Messerli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pool, J., Kaihlanen, P., Lewis, G. et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 15, 495–498 (2001). https://doi.org/10.1038/sj.jhh.1001217

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001217

Keywords

This article is cited by

Search

Advanced search

Quick links